Evaluation of safety and tolerance of microencapsulated Lactobacillus reuteri NCIMB 30242 in a yogurt formulation: A randomized, placebo-controlled, double-blind study

Food and Chemical Toxicology

Volumn 50, Issue 6, 2012, Pages 2216-2223

  Jones, Mitchell L ^a,b   Martoni, Christopher J ^b   Tamber, Sandeep ^b   Parent, Mathieu ^b   Prakash, Satya ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITÉ DU QUÉBEC À MONTRÉAL   (Canada)

Author keywords

Adverse events; Bile salt hydrolase; Lactobacillus; Microencapsulation; Probiotic; Safety

Indexed keywords

ALGINATE POLYLYSINE ALGINATE; BILE ACID; CARDIOVIVA; PLACEBO; PROBIOTIC AGENT; UNCLASSIFIED DRUG; YOGHURT;

ADULT; ARTICLE; BODY MASS; BODY WEIGHT; BRONCHITIS; CLINICAL CHEMISTRY; COLONY FORMING UNIT; CONTROLLED STUDY; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; ENTHESOPATHY; ERYTHROCYTE COUNT; EVENING DOSAGE; FECES ANALYSIS; FEMALE; HEART RATE; HEMATOCRIT; HEMATOLOGICAL PARAMETERS; HUMAN; HUMAN EXPERIMENT; LACTOBACILLUS REUTERI; LACTOBACILLUS REUTERI NCIMB 30242; LEUKOCYTE COUNT; MALE; MICROENCAPSULATION; MORBIDITY; MORNING DOSAGE; MOUTH TEMPERATURE; MULTICENTER STUDY; NORMAL HUMAN; OTITIS MEDIA; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SIDE EFFECT; SKIN TUMOR; SYSTOLIC BLOOD PRESSURE; THROMBOCYTE COUNT; TONSILLITIS; TREATMENT DURATION; VIRUS INFECTION;

ADOLESCENT; ADULT; AGED; BILE ACIDS AND SALTS; BLOOD CELL COUNT; BLOOD CHEMICAL ANALYSIS; BODY MASS INDEX; BODY WEIGHT; DOUBLE-BLIND METHOD; DRUG COMPOUNDING; FECES; FEMALE; FERMENTATION; HEMODYNAMICS; HUMANS; HYPERCHOLESTEROLEMIA; LACTOBACILLUS REUTERI; MALE; MIDDLE AGED; PROBIOTICS; YOGURT; YOUNG ADULT;

LACTOBACILLUS; LACTOBACILLUS REUTERI;

EID: 84860528207     PISSN: 02786915     EISSN: 18736351     Source Type: Journal    
DOI: 10.1016/j.fct.2012.03.010     Document Type: Article

References (47)

1. Agency for Healthcare Research and Quality, 2011 Safety of Probiotics to Reduce Risk and Prevent or Treat Disease. 11-E007 ed., pp. 1-645.
2. Batta A.K., Salen G., Batta P., Tint G.S., Alberts D.S., Earnest D.L. Simultaneous quantitation of fatty acids, sterols and bile acids in human stool by capillary gas-liquid chromatography. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2002, 775:153-161.
3. Bays H.E., Davidson M.H., Massaad R., Flaim D., Lowe R.S., Tershakovec A.M., Jones-Burton C. Safety and efficacy of ezetimibe added on to rosuvastatin 5 or 10 mg versus up-titration of rosuvastatin in patients with hypercholesterolemia (the ACTE Study). Am. J. Cardiol. 2011, 108:523-530.
4. Bosscher D., Breynaert A., Pieters L., Hermans N. Food-based strategies to modulate the composition of the intestinal microbiota and their associated health effects. J. Physiol. Pharmacol. 2009, 60(Suppl 6):5-11.
5. Branton W.B., Jones M.L., Tomaro-Duchesneau C., Martoni C.J., Prakash S. In vitro characterization and safety of the probiotic strain Lactobacillus reuteri cardioviva NCIMB 30242. Int. J. Probiotics Prebiotics 2011, 6:1-12.
6. Burton J.P., Cowley S., Simon R.R., McKinney J., Wescombe P.A., Tagg J.R. Evaluation of safety and human tolerance of the oral probiotic Streptococcus salivarius K12: a randomized, placebo-controlled, double-blind study. Food Chem. Toxicol. 2011, 49:2356-2364.
7. Casas I.A., Dobrogosz W.J. Validation of the probiotic concept: Lactobacillus reuteri confers broad-spectrum protection against disease in humans and animals. Microbiol. Ecol. Health. Dis. 2000, 12:247-285.
8. Coccorullo P., Strisciuglio C., Martinelli M., Miele E., Greco L., Staiano A. Lactobacillus reuteri (DSM 17938) in infants with functional chronic constipation: a double-blind, randomized, placebo-controlled study. J. Pediatr. 2010, 157:598-602.
9. Connolly E., Abrahamsson T., Bjorksten B. Safety of D(-)-lactic acid producing bacteria in the human infant. J. Pediatr. Gastroenterol. Nutr. 2005, 41:489-492.
10. Del P.M., Carmagnola S., Ballare M., Sartori M., Orsello M., Balzarini M., Pagliarulo M., Tari R., Anderloni A., Strozzi G.P., Mogna L., Sforza F., Capurso L. Is microencapsulation the future of probiotic preparations? The increased efficacy of gastro-protected probiotics. Gut. Microbes. 2011, 2:120-123.
11. Dobrogosz W.J., Peacock T.J., Hassan H.M. Evolution of the probiotic concept from conception to validation and acceptance in medical science. Adv. Appl. Microbiol. 2010, 72:1-41.
12. EFSA Panel on Biological Hazards, 2009. Scientific opinion on the maintenance of the list of QPS microorganisms intentionally added to food or feed (2009 update). EFSA J. 7, 1431.
13. Ford E.S., Li C., Pearson W.S., Zhao G., Mokdad A.H. Trends in hypercholesterolemia, treatment and control among United States adults. Int. J. Cardiol. 2010, 140:226-235.
14. Gareau M.G., Sherman P.M., Walker W.A. Probiotics and the gut microbiota in intestinal health and disease. Nat. Rev. Gastroenterol. Hepatol. 2010, 7:503-514.
15. Gibson, G.R., Brummer, R.J., Isolauri, E., Lochs, H., Morelli, L., Ockhuizen, T., Rowland, I.R., Schrezenmeir, J., Stanton, C., Verbeke, K., 2011. The design of probiotic studies to substantiate health claims. Gut Microbes. 2.
16. Hansel B., Nicolle C., Lalanne F., Tondu F., Lassel T., Donazzolo Y., Ferrieres J., Krempf M., Schlienger J.L., Verges B., Chapman M.J., Bruckert E. Effect of low-fat, fermented milk enriched with plant sterols on serum lipid profile and oxidative stress in moderate hypercholesterolemia. Am. J. Clin. Nutr. 2007, 86:790-796.
17. Holzapfel W.H., Haberer P., Snel J., Schillinger U., Huis in't Veld J.H.J. Overview of gut flora and probiotics. Int.J. Food Microbiol. 1998, 41:85-101.
18. Huang Y., Adams M.C. In vitro assessment of the upper gastrointestinal tolerance of potential probiotic dairy propionibacteria. Int.J. Food Microbiol. 2004, 91:253-260.
19. Jones, M.L., Martoni, C.J., Parent, M., Prakash, S., 2011. Cholesterol-lowering efficacy of a microencapsulated bile salt hydrolase-active Lactobacillus reuteri NCIMB 30242 yoghurt formulation in hypercholesterolaemic adults. Br. J. Nutr. 1-9.
20. Kurmann J.A., Rasic J.L., Kroger M. Encyclopedia of Fermented Fresh Milk ProductsVan Nostrand Reinhold 1992, New York.
21. Lee D.Y., Seo Y.S., Rayamajhi N., Kang M.L., Lee S.I., Yoo H.S. Isolation, characterization, and evaluation of wild isolates of Lactobacillus reuteri from pig feces. J. Microbiol. 2009, 47:663-672.
22. Lepercq P., Relano P., Cayuela C., Juste C. Bifidobacterium animalis strain DN-173 010 hydrolyses bile salts in the gastrointestinal tract of pigs. Scand. J. Gastroenterol. 2004, 39:1266-1271.
23. Marteau P., Cuillerier E., Meance S., Gerhardt M.F., Myara A., Bouvier M., Bouley C., Tondu F., Bommelaer G., Grimaud J.C. Bifidobacterium animalis strain DN-173 010 shortens the colonic transit time in healthy women: a double-blind, randomized, controlled study. Aliment. Pharmacol. Ther. 2002, 16:587-593.
24. Martoni, C., Bhathena, J., Jones, M.L., Urbanska, A.M., Chen, H., Prakash, S., 2007. Investigation of microencapsulated BSH active Lactobacillus in the simulated human GI tract. J. Biomed. Biotechnol. http://dx.doi.org/10.1155/2007/13684.
25. Martoni C., Bhathena J., Urbanska A.M., Prakash S. Microencapsulated bile salt hydrolase producing Lactobacillus reuteri for oral targeted delivery in the gastrointestinal tract. Appl. Microbiol. Biotechnol. 2008, 81:225-233.
26. Molin G., Andersson R., Ahrne S., Lonner C., Marklinder I., Johansson M.L., Jeppsson B., Bengmark S. Effect of fermented oatmeal soup on the cholesterol level and the Lactobacillus colonization of rat intestinal mucosa. Antonie Van Leeuwenhoek 1992, 61:167-173.
27. Naito S., Hayashidani H., Kaneko K., Ogawa M., Benno Y. Development of intestinal lactobacilli in normal piglets. J. Appl. Bacteriol. 1995, 79:230-236.
28. Narayan S.S., Jalgaonkar S., Shahani S., Kulkarni V.N. Probiotics: current trends in the treatment of diarrhoea. Hong Kong Med. J. 2010, 16:213-218.
29. Nawrocki J.W., Weiss S.R., Davidson M.H., Sprecher D.L., Schwartz S.L., Lupien P.J., Jones P.H., Haber H.E., Black D.M. Reduction of LDL cholesterol by 25-60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler. Thromb. Vasc. Biol. 1995, 15:678-682.
30. Oliva, S., Di, N.G., Ferrari, F., Mallardo, S., Rossi, P., Patrizi, G., Cucchiara, S., Stronati, L., 2011. Randomised clinical trial: the effectiveness of Lactobacillus reuteri ATCC 55730 rectal enema in children with active distal ulcerative colitis. Aliment. Pharmacol. Ther.
31. Parkes G.C., Sanderson J.D., Whelan K. Treating irritable bowel syndrome with probiotics: the evidence. Proc. Nutr. Soc. 2010, 69:187-194.
32. Plana N., Nicolle C., Ferre R., Camps J., Cos R., Villoria J., Masana L. Plant sterol-enriched fermented milk enhances the attainment of LDL-cholesterol goal in hypercholesterolemic subjects. Eur. J. Nutr. 2008, 47:32-39.
33. Prakash S., Tomaro-Duchesneau C., Saha S., Cantor A. The gut microbiota and human health with an emphasis on the use of microencapsulated bacterial cells. J. Biomed. Biotechnol. 2011, 2011:981214.
34. Rauch, M., Lynch, S., 2011. The potential for probiotic manipulation of the gastrointestinal microbiome. Curr. Opin. Biotechnol.
35. Rosander A., Connolly E., Roos S. Removal of antibiotic resistance gene-carrying plasmids from Lactobacillus reuteri ATCC 55730 and characterization of the resulting daughter strain, L. reuteri DSM 17938. Appl. Environ. Microbiol. 2008, 74:6032-6040.
36. Salminen S., von Wright A. Lactic Acid Bacteria 1 ed 1993, Marcel Dekker Ltd., New York.
37. Sanz Y., Santacruz A., Gauffin P. Gut microbiota in obesity and metabolic disorders. Proc. Nutr. Soc. 2010, 69:434-441.
38. Schiff E.R., Small N.C., Dietschy J.M. Characterization of the kinetics of the passive and active transport mechanisms for bile acid absorption in the small intestine and colon of the rat. J. Clin. Invest 1972, 51:1351-1362.
39. Taranto M.P., Vera J.L., Hugenholtz J., de Valdez G.F., Sesma F. Lactobacillus reuteri CRL1098 produces cobalamin. J. Bacteriol. 2003, 185:5643-5647.
40. Valderas J.M., Kotzeva A., Espallargues M., Guyatt G., Ferrans C.E., Halyard M.Y., Revicki D.A., Symonds T., Parada A., Alonso J. The impact of measuring patient-reported outcomes in clinical practice. a systematic review of the literature. Qual. Life Res. 2008, 17:179-193.
41. Vanderhoof J.A., Mitmesser S.H. Probiotics in the management of children with allergy and other disorders of intestinal inflammation. Benef. Microbes. 2010, 1:351-356.
42. Vasile N., Ghindea R., Vassu T. Probiotics-an alternative treatment for various diseases. Roum. Arch. Microbiol. Immunol. 2011, 70:54-59.
43. Weizman Z., Alsheikh A. Safety and tolerance of a probiotic formula in early infancy comparing two probiotic agents: a pilot study. J. Am. Coll. Nutr. 2006, 25:415-419.
44. WHO, 2001 Evaluation of Health and Nutritional Properties of Probiotics in Food including Powder Milk with Live Lactic Acid Bacteria. 85 ed., pp. 1-50.
45. Wind R.D., Tolboom H., Klare I., Huys G., Knol J. Tolerance and safety of the potentially probiotic strain Lactobacillus rhamnosus PRSF-L477: a randomised, double-blind placebo-controlled trial in healthy volunteers. Br. J. Nutr. 2010, 104:1806-1816.
46. Wolf B.W., Garleb K.A., Ataya D.G., Casas I.A. Safety and Tolerance of Lactobacillus reuteri in Healthy Adult Male Subjects. Microbial. Ecol. Health Dis. 1995, 8:41-50.
47. Wolf B.W., Wheeler K.B., Ataya D.G., Garleb K.A. Safety and tolerance of Lactobacillus reuteri supplementation to a population infected with the human immunodeficiency virus. Food Chem. Toxicol. 1998, 36:1085-1094.